SCYNEXIS (SCYX) vs Zhengye Biotechnology (ZYBT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
SCYNEXIS (SCYX) has outperformed Zhengye Biotechnology (ZYBT) over the past year, losing 32.1% versus a loss of 62.7%. Zhengye Biotechnology is the larger company by market cap ($55.4 million vs $41.1 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SCYX | ZYBT |
|---|---|---|
| Share price | $4.13 | $1.17 |
| Market cap | $41.09M | $55.45M |
| 1-day change | -2.13% | +1.75% |
| YTD return | -16.53% | -0.01% |
| 1-year return | -32.11% | -62.67% |
| 5-year return | -90.53% | — |
| EPS (TTM) | $-0.89 | $-0.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.12 | $8.01 |
| 52-week low | $3.53 | $0.616 |
| Distance from 52-week high | -54.71% | -85.39% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +779.66% | — |
| Average volume | 279.10K | 5.10M |
| Shares outstanding | 9.95M | 47.39M |
| Employees | 18 | 269 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SCYX has outperformed ZYBT by 30.6 percentage points over the past year.
About SCYNEXIS
SCYX stock →SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence.
Health Care · Biotechnology: Pharmaceutical Preparations · 18 employees
About Zhengye Biotechnology
ZYBT stock →Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine.
Health Care · Biotechnology: Pharmaceutical Preparations · 269 employees
SCYX vs ZYBT FAQ
Which is bigger, SCYNEXIS or Zhengye Biotechnology?
Zhengye Biotechnology (ZYBT) is larger, with a market capitalization of $55.45M compared with $41.09M for SCYNEXIS (SCYX).
Which stock has performed better over the past year, SCYX or ZYBT?
SCYX returned -32.11% over the past 12 months, compared with -62.67% for ZYBT (price return, excluding dividends). Past performance does not predict future results.
Are SCYNEXIS and Zhengye Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.